{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:21:54Z","timestamp":1793830914968,"version":"4.6.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T00:00:00Z","timestamp":1743897600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T00:00:00Z","timestamp":1743897600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1245\/s10434-025-17269-x","type":"journal-article","created":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T17:08:32Z","timestamp":1743959312000},"page":"4326-4334","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluating the Role of Hyperthermic Intraperitoneal Chemotherapy in Cytoreductive Surgery for Advanced-Stage Ovarian Cancer"],"prefix":"10.1245","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-5016-8838","authenticated-orcid":false,"given":"Adrian","family":"Kohut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew L.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaagn","family":"Andikyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Yasukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Nguy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Karachristos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Nywening","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"Mor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhika","family":"Gogoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua G.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff F.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Rutherford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,6]]},"reference":[{"key":"17269_CR1","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2147\/IJWH.S197604","volume":"11","author":"Z Momenimovahed","year":"2019","unstructured":"Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health. 2019;11:287\u201399. https:\/\/doi.org\/10.2147\/IJWH.S197604.","journal-title":"Int J Womens Health."},{"issue":"4","key":"17269_CR2","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2165\/11598890-000000000-00000","volume":"51","author":"C Hasovits","year":"2012","unstructured":"Hasovits C, Clarke S. Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics. Clin Pharmacokinet. 2012;51(4):203\u201324. https:\/\/doi.org\/10.2165\/11598890-000000000-00000.","journal-title":"Clin Pharmacokinet."},{"issue":"1","key":"17269_CR3","first-page":"1","volume":"62","author":"RL Dedrick","year":"1978","unstructured":"Dedrick RL, Myers CE, Bungay PM, DeVita VT. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978;62(1):1\u201311.","journal-title":"Cancer Treat Rep."},{"issue":"6","key":"17269_CR4","first-page":"1712","volume":"47","author":"S Zimm","year":"1987","unstructured":"Zimm S, Cleary SM, Lucas WE, et al. Phase I\/pharmacokinetic study of intraperitoneal cisplatin and etoposide. Cancer Res. 1987;47(6):1712\u20136.","journal-title":"Cancer Res."},{"issue":"3","key":"17269_CR5","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/PPO.0b013e3181a58d95","volume":"15","author":"K Van der Speeten","year":"2009","unstructured":"Van der Speeten K, Stuart OA, Sugarbaker PH. Pharmacokinetics and pharmacodynamics of perioperative cancer chemotherapy in peritoneal surface malignancy. Cancer J. 2009;15(3):216\u201324. https:\/\/doi.org\/10.1097\/PPO.0b013e3181a58d95.","journal-title":"Cancer J."},{"issue":"6","key":"17269_CR6","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/BF00686048","volume":"25","author":"G Los","year":"1990","unstructured":"Los G, Mutsaers PH, Lenglet WJ, Baldew GS, McVie JG. Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. Cancer Chemother Pharmacol. 1990;25(6):389\u201394. https:\/\/doi.org\/10.1007\/BF00686048.","journal-title":"Cancer Chemother Pharmacol."},{"issue":"10","key":"17269_CR7","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1200\/JCO.1987.5.10.1607","volume":"5","author":"SB Howell","year":"1987","unstructured":"Howell SB, Zimm S, Markman M, et al. Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy. J Clin Oncol. 1987;5(10):1607\u201312. https:\/\/doi.org\/10.1200\/JCO.1987.5.10.1607.","journal-title":"J Clin Oncol."},{"issue":"3","key":"17269_CR8","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.ygyno.2006.09.012","volume":"103","author":"DS Alberts","year":"2006","unstructured":"Alberts DS, Markman M, Muggia F, et al. Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancer. Gynecol Oncol. 2006;103(3):783\u201392. https:\/\/doi.org\/10.1016\/j.ygyno.2006.09.012.","journal-title":"Gynecol Oncol."},{"issue":"4","key":"17269_CR9","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"M Markman","year":"2001","unstructured":"Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the gynecologic oncology group, southwestern oncology group, and eastern cooperative oncology group. J Clin Oncol. 2001;19(4):1001\u20137. https:\/\/doi.org\/10.1200\/JCO.2001.19.4.1001.","journal-title":"J Clin Oncol."},{"issue":"1","key":"17269_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa052985","volume":"354","author":"DK Armstrong","year":"2006","unstructured":"Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34\u201343. https:\/\/doi.org\/10.1056\/NEJMoa052985.","journal-title":"N Engl J Med."},{"issue":"26","key":"17269_CR11","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1200\/JCO.2015.61.4776","volume":"33","author":"AA Wright","year":"2015","unstructured":"Wright AA, Cronin A, Milne DE, et al. Use and effectiveness of intraperitoneal chemotherapy for treatment of ovarian cancer. J Clin Oncol. 2015;33(26):2841\u20137. https:\/\/doi.org\/10.1200\/JCO.2015.61.4776.","journal-title":"J Clin Oncol."},{"issue":"13","key":"17269_CR12","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1200\/JCO.2014.55.9898","volume":"33","author":"D Tewari","year":"2015","unstructured":"Tewari D, Java JJ, Salani R, et al. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2015;33(13):1460\u20136. https:\/\/doi.org\/10.1200\/JCO.2014.55.9898.","journal-title":"J Clin Oncol."},{"issue":"Suppl 8","key":"17269_CR13","doi-asserted-by":"publisher","first-page":"viii40","DOI":"10.1093\/annonc\/mdx451","volume":"28","author":"BJ Monk","year":"2017","unstructured":"Monk BJ, Chan JK. Is intraperitoneal chemotherapy still an acceptable option in primary adjuvant chemotherapy for advanced ovarian cancer? Ann Oncol. 2017;28(Suppl 8):viii40\u20135. https:\/\/doi.org\/10.1093\/annonc\/mdx451.","journal-title":"Ann Oncol."},{"issue":"3","key":"17269_CR14","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa1708618","volume":"378","author":"WJ van Driel","year":"2018","unstructured":"van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1708618.","journal-title":"N Engl J Med."},{"issue":"10","key":"17269_CR15","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S1470-2045(23)00396-0","volume":"24","author":"SL Aronson","year":"2023","unstructured":"Aronson SL, Lopez-Yurda M, Koole SN, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial. Lancet Oncol. 2023;24(10):1109\u201318. https:\/\/doi.org\/10.1016\/S1470-2045(23)00396-0.","journal-title":"Lancet Oncol."},{"key":"17269_CR16","first-page":"2825","volume":"12","author":"F Pedregosa","year":"2011","unstructured":"Pedregosa F, Varoquaux G, Gramfort A, et al. Scikit-learn: machine learning in python. J Mach Learn Res. 2011;12:2825\u201330.","journal-title":"J Mach Learn Res."},{"issue":"5","key":"17269_CR17","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamasurg.2022.0143","volume":"157","author":"MC Lim","year":"2022","unstructured":"Lim MC, Chang SJ, Park B, et al. Survival after hyperthermic intraperitoneal chemotherapy and primary or interval cytoreductive surgery in ovarian cancer: a randomized clinical trial. JAMA Surg. 2022;157(5):374\u201383. https:\/\/doi.org\/10.1001\/jamasurg.2022.0143.","journal-title":"JAMA Surg."},{"issue":"4","key":"17269_CR18","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1245\/s10434-021-11087-7","volume":"29","author":"CCP Antonio","year":"2022","unstructured":"Antonio CCP, Alida GG, Elena GG, et al. Cytoreductive surgery with or without HIPEC after neoadjuvant chemotherapy in ovarian cancer: a phase 3 clinical trial. Ann Surg Oncol. 2022;29(4):2617\u201325. https:\/\/doi.org\/10.1245\/s10434-021-11087-7.","journal-title":"Ann Surg Oncol."},{"issue":"8","key":"17269_CR19","doi-asserted-by":"publisher","first-page":"e2013940","DOI":"10.1001\/jamanetworkopen.2020.13940","volume":"3","author":"Z Lei","year":"2020","unstructured":"Lei Z, Wang Y, Wang J, et al. Evaluation of cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for stage III epithelial ovarian cancer. JAMA Netw Open. 2020;3(8):e2013940. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.13940.","journal-title":"JAMA Netw Open."},{"issue":"11","key":"17269_CR20","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1001\/jamasurg.2023.3944","volume":"158","author":"JY Lee","year":"2023","unstructured":"Lee JY, Lee YJ, Son JH, et al. Hyperthermic intraperitoneal chemotherapy after interval cytoreductive surgery for patients with advanced-stage ovarian cancer who had received neoadjuvant chemotherapy. JAMA Surg. 2023;158(11):1133\u201340. https:\/\/doi.org\/10.1001\/jamasurg.2023.3944.","journal-title":"JAMA Surg."},{"issue":"5","key":"17269_CR21","doi-asserted-by":"publisher","first-page":"100586","DOI":"10.1016\/j.esmoop.2022.100586","volume":"7","author":"P Filis","year":"2022","unstructured":"Filis P, Mauri D, Markozannes G, Tolia M, Filis N, Tsilidis K. Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials. ESMO Open. 2022;7(5):100586. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100586.","journal-title":"ESMO Open."},{"issue":"5","key":"17269_CR22","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.3390\/cancers15051402","volume":"15","author":"OG Huffman","year":"2023","unstructured":"Huffman OG, Chau DB, Dinicu AI, DeBernardo R, Reizes O. Mechanistic insights on hyperthermic intraperitoneal chemotherapy in ovarian cancer. Cancers. 2023;15(5):1402. https:\/\/doi.org\/10.3390\/cancers15051402.","journal-title":"Cancers"},{"key":"17269_CR23","doi-asserted-by":"publisher","first-page":"100926","DOI":"10.1016\/j.gore.2022.100926","volume":"39","author":"R Vanguri","year":"2022","unstructured":"Vanguri R, Benhamida J, Young JH, et al. Understanding the impact of chemotherapy on the immune landscape of high-grade serous ovarian cancer. Gynecol Oncol Rep. 2022;39:100926. https:\/\/doi.org\/10.1016\/j.gore.2022.100926.","journal-title":"Gynecol Oncol Rep."},{"issue":"1","key":"17269_CR24","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41389-022-00419-1","volume":"11","author":"Y Shen","year":"2022","unstructured":"Shen Y, Ren Y, Chen K, et al. The impact of neoadjuvant chemotherapy on the tumor microenvironment in advanced high-grade serous carcinoma. Oncogenesis. 2022;11(1):43. https:\/\/doi.org\/10.1038\/s41389-022-00419-1.","journal-title":"Oncogenesis."},{"key":"17269_CR25","doi-asserted-by":"publisher","first-page":"e2100239","DOI":"10.1200\/PO.21.00239","volume":"6","author":"TH Dellinger","year":"2022","unstructured":"Dellinger TH, Han ES, Raoof M, et al. Hyperthermic intraperitoneal chemotherapy-induced molecular changes in humans validate preclinical data in ovarian cancer. JCO Precis Oncol. 2022;6:e2100239. https:\/\/doi.org\/10.1200\/PO.21.00239.","journal-title":"JCO Precis Oncol."},{"issue":"2","key":"17269_CR26","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1379\/csc-99r.1","volume":"10","author":"DR Ciocca","year":"2005","unstructured":"Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones. 2005;10(2):86\u2013103. https:\/\/doi.org\/10.1379\/csc-99r.1.","journal-title":"Cell Stress Chaperones."},{"issue":"1","key":"17269_CR27","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/10717544.2020.1862364","volume":"28","author":"DR L\u00f6ke","year":"2021","unstructured":"L\u00f6ke DR, Helderman RFCP, Franken NAP, et al. Simulating drug penetration during hyperthermic intraperitoneal chemotherapy. Drug Deliv. 2021;28(1):145\u201361. https:\/\/doi.org\/10.1080\/10717544.2020.1862364.","journal-title":"Drug Deliv."},{"issue":"16","key":"17269_CR28","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1200\/JCO.18.01568","volume":"37","author":"JL Walker","year":"2019","unstructured":"Walker JL, Brady MF, Wenzel L, et al. Randomized trial of intravenous versus intraperitoneal chemotherapy plus Bevacizumab in advanced ovarian carcinoma: an NRG oncology\/gynecologic oncology group study. J Clin Oncol. 2019;37(16):1380\u201390. https:\/\/doi.org\/10.1200\/JCO.18.01568.","journal-title":"J Clin Oncol."},{"key":"17269_CR29","unstructured":"NCT05659381: Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer (HOTT). GOG Foundation; 2025. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05659381"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17269-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-17269-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17269-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T16:14:35Z","timestamp":1746288875000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-17269-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,6]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["17269"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-17269-x","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,6]]},"assertion":[{"value":"10 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Adrian Kohut, Matthew L. Anderson, Vaagn Andikyan, Maya Yasukawa, Lindsey Nguy, Andreas Karachristos, Timothy Nywening, Gil Mor, Radhika Gogoi, Joshua G. Cohen, Jeff F. Lin, and Thomas J. Rutherford deny potential conflicts of interest, including financial interests, activities, relationships, and affiliations, that may be relevant to the contents of this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}